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One possible intervention to interrupt the deleterious effects of the renin-angiotensin system
is suppression of angiotensin II (Ang II) formation by inhibition of angiotensin-converting
enzyme (ACE). However, ACE inhibition incompletely suppresses Ang II formation and
also leads to accumulation of bradykinin. Angiotensin II type 1 (AT1) receptors are believed
to promote the known deleterious effects of Ang II. Therefore, AT1 receptor antagonists have
been recently introduced into therapy for hypertension and congestive heart failure (CHF).
Although there are significant differences between the effects of AT1 receptor antagonists and
ACE inhibitors including the unopposed stimulation of angiotensin II type 2 (AT2) receptors
by AT1 receptor antagonists, the discussion of whether ACE inhibitors, AT1 receptor
antagonists or the combination of both are superior in the pharmacotherapy of CHF is still
largely theoretical. Accordingly, AT1 receptor antagonists are still investigational.
Angiotensin-converting enzyme inhibitors remain first line therapy in patients with CHF due
to systolic dysfunction. However, in patients not able to tolerate ACE inhibitor induced side
effects, in particular cough, AT1 receptor antagonism is a good alternative. In clinical practice,
emphasis should be placed on increasing the utilization of ACE inhibitors, as more than 50%
of patients with CHF do not receive ACE inhibitors. In addition, the majority of those on
ACE inhibitors receive doses lower than the dosage used in the large clinical trials. Although
not yet completely proved, it is likely that high doses of ACE inhibition are superior to low
doses with respect to prognosis and symptoms. (J Am Coll Cardiol 1999;33:1163–73) ©
1999 by the American College of Cardiology
One of the major consequences of reduced cardiac perfor-
mance in chronic congestive heart failure (CHF) is activa-
tion of the sympathetic nervous system and the renin
angiotensin system (RAS) (1,2). Angiotensin (Ang) II is
believed to mediate the deleterious effects of RAS activa-
tion. Apart from other effects, Ang II induces vasoconstric-
tion, aldosterone secretion and possibly activation of the
sympathetic nervous system and norepinephrine release (3).
Vasoconstriction and volume overload lead to augmented
wall stress which increases myocardial oxygen consumption
(4). Together with other mechanisms (5,6), this promotes
myocardial dysfunction, which further stimulates the RAS
as well as the sympathetic nervous system.
One possible intervention to interrupt this vicious cycle
may be suppression of Ang II formation by inhibition of
ACE. Several large clinical trials have shown that ACE
inhibitors reduce mortality and morbidity in patients with
CHF (7–11). However, ACE inhibition incompletely sup-
presses ACE activity and thus Ang II formation (12,13).
Further, Ang II production may occur independently of
ACE via other pathways (14,15). This may explain why
plasma aldosterone concentrations tend to rise on ACE
inhibitors after an initial fall (16).
Angiotensin II type 1 (AT1) receptors are believed to
promote the known deleterious effects of Ang II. Therefore,
AT1 receptor antagonists have been recently introduced
into therapy for hypertension and CHF (17). Angiotensin II
type 2 (AT2) receptor mediated effects in CHF are largely
unknown but may be involved in antihypertrophic, pro-
apoptotic effects on the myocardium (18). These effects
could be important since AT1 receptor antagonism leads to
an increase in Ang II levels (19). In addition, Ang II is
cleaved to Ang III and IV (20). These degraded peptides
have been claimed to have important biologic actions (21)
not inhibited by AT1 receptor antagonists.
Furthermore, in contrast to AT1 receptor antagonists,
ACE inhibition leads to accumulation of bradykinin, which
is responsible for some of the side effects of ACE inhibitors
but may also have a therapeutic benefit in CHF (22,23).
It is apparent from these observations that there are
significant differences between the AT1 receptor antago-
nists and ACE inhibitors, beyond issues of tolerability and
selective blockade of the AT1 receptor. Thus, AT1 receptor
antagonists are not just “better ACE inhibitors.” Figure 1
depicts the site of action of ACE-inhibitors and AT1
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receptor antagonists and the theoretical differences between
these two classes of drugs.
This article will focus on properties of ACE inhibitors
and AT1 receptor antagonists and theoretical differences
between them. The significance of these differences with
respect to morbidity and mortality in CHF are largely
unknown. Nevertheless, a clearer understanding may be
helpful in planning new clinical studies and individualizing
therapy for patients. This review will also endeavor to
summarize the clinical data comparing these two drug
classes with an emphasis on underutilization and suboptimal
dosage of ACE inhibitors in therapy for CHF and the
possible impact of AT1 receptor antagonists on these issues.
THEORETICAL ISSUES OF ACE
INHIBITORS VERSUS AT1 RECEPTOR ANTAGONISTS
Differences that may exist between the two classes of drugs
are as follows (Fig. 1):
1) Angiotensin-converting enzyme inhibition decreases ac-
tivity at all Ang receptors. Angiotensin II type 1 receptor
antagonists are selective, therefore Ang may act unop-
posed on other receptors. Angiotensin II type 1 receptor
mediated effects may be suppressed more completely by
AT1 receptor antagonists,
2) angiotensin converting enzyme inhibition causes signif-
icant bradykinin accumulation, and
3) the sympathetic nervous system may be differentially
influenced by the two classes of drugs.
Angiotensin receptors. There are believed to be four Ang
receptors—AT1 through AT4. The AT1 receptor is be-
lieved to mediate the classic actions of Ang II such as
vasoconstriction and sodium and water retention and also
seems to play a role in cardiovascular remodeling (Fig. 1)
(5,24–27). The AT2 receptor appears to have a role in
cellular growth and remodeling; however, other functions
are less well defined. The role of the other Ang receptors is
less well characterized.
Suppression of AT1 receptor mediated effects. Angio-
tensin II type 1 receptor antagonists may suppress the AT1
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
Ang 5 angiotensin
AT1 5 angiotensin II type 1
AT2 5 angiotensin II type 2
B1 5 bradykinin type 1
B2 5 bradykinin type 2
CHF 5 congestive heart failure
MCP-1 5 monocyte chemoattractant protein-1
PAI-1 5 plasminogen activator inhibitor C-1
RAS 5 renin angiotensin system
t-PA 5 tissue plasminogen activator
Figure 1. Cascades of RAS and kinins and mechanisms of action of ACE inhibitors and AT1 receptor antagonists. Conversion from Ang
I to Ang II promoted by ACE and non-ACE pathways. Accordingly, ACE inhibitors cannot completely inhibit Ang II formation.
Angiotensin II effects are mediated by AT1- and AT2-receptors. While AT1-receptor mediated effects are well defined, AT2-receptor
mediated effects are less clear. Angiotensin II type 1 receptor effects can be inhibited by AT1 receptor antagonists while AT2 receptor
mediated effects and the formation of Ang III and IV are unconstrained by them. Angiotensin II type 2 receptor stimulation might increase
bradykinin levels. Thus, it is possible that increased bradykinin levels may be caused not only by ACE inhibition, but also by AT1 receptor
antagonism to a lesser extent. AT 5 Ang II receptors; t-PA 5 tissue plasminogen activator; SNS 5 sympathetic nervous system; GFR 5
growth factors; PAI 5 plasminogen activator inhibitor. White arrows indicate enzymatic activation, black arrows formation of substances,
double arrows receptor or substance mediated effects.
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receptor mediated effects more completely than ACE in-
hibitors (28). Angiotensin II type 1 receptor antagonists
block these effects directly at the receptor site while ACE
inhibitors act only indirectly by inhibition of Ang II
formation. However, this inhibition of Ang II formation is
incomplete only. Plasma levels of Ang II after chronic ACE
inhibition tend to return towards initial values (29), prob-
ably due to a reactive rise in renin and Ang I levels as well
as Ang II formation by alternative pathways such as cardiac
chymase (30). Nevertheless, dosage of ACE inhibitors may
affect Ang II levels since only high doses have been shown
to suppress plasma ACE activity almost completely
throughout 24 h in chronic therapy (31). Low to moderately
high doses suppress it only partially (13,32). This finding
concurs with the findings that high ACE inhibitor doses
lower aldosterone concentration (33) and suppress Ang II
formation in plasma more effectively (12).
Cellular growth and remodeling. Fibrosis and remodel-
ing, now well recognized processes in various cardiac dis-
eases, may impair cardiac function (34,35). Decompensated
cardiac failure is associated with increased mRNA expres-
sion of extracellular matrix proteins which manifests as
cardiac fibrosis (36). Angiotensin II type 1 receptors appear
to be involved in this process (37–39) while AT2 receptors
may counteract the AT1 mediated effects (37,40).
The differential distribution of AT1 and AT2 receptors
in normal and failing human hearts has recently been shown
(41). Focal areas of very high AT2 receptor density were
localized to areas of fibroblast activity and collagen deposi-
tion in the failing human heart. The infarct/noninfarct
border zone also showed high AT2 and ACE levels (41).
This suggests that the RAS is involved in fibrotic repair
after cardiac insults. In response to Ang II, rat cardiac
fibroblasts and myofibroblasts produce transforming growth
factor b which may stimulate cardiac fibrosis. This effect can
be attenuated by losartan and to a lesser extent AT2
antagonists (38). Angiotensin II type 1 receptor antagonists
used in the rat infarct model of CHF have been shown to
derive part of their beneficial effect from high Ang II levels
on unopposed AT2 receptors (40). In addition, AT2 block-
ade in rats following myocardial infarction showed signifi-
cant reductions in interstitial cell DNA synthesis and a
decrease in cardiac output, not observed when an AT1
antagonist was used (42), supporting the role of AT2
receptors in myocardial repair. However, results in models
of acute ischemia using AT2 receptor antagonism are
contradictory. These studies showed improved recovery
after ischemia-reperfusion in isolated working rat hearts
(43). In addition, AT2 receptors may stimulate apoptosis
(18), which may be related to myocardial cell loss in CHF
(44). Thus, it is not yet clear whether stimulation of AT2
receptors is beneficial in CHF. Although the inhibitory
effects on remodeling and cardiac fibrosis as well as vasodi-
latation are believed to be beneficial, it is conceivable that
the net effect is dependent on the stage and the underlying
cause of CHF. This may be supported in that Ang receptors
appear to have different functions in animal models of CHF
(40), myocardial infarction (42,43) and hypertension (39),
suggesting different roles in different pathological processes.
Confounding the interpretation of results further is the
cross species difference in receptors, exemplified by the
differential chromosomal distribution of receptors between
humans and animals (45).
Angiotensin II may also play a role in vascular pathology
which seems to be mediated by AT1 receptors. The appli-
cation of Ang II to the rat carotid artery has been shown to
induce adventitial thickening in vivo (46). Moreover, mono-
cyte infiltration into vessel walls partially mediated by
monocyte chemoattractant protein-1 (MCP-1) is believed
to play a role in atherogenesis. Angiotensin II increases
MCP-1 levels, while losartan attenuates this effect (47). In
addition, the platelet derived growth factors a and b,
implicated in the pathogenesis of atherosclerosis (48), are
markedly diminished by AT1 receptor antagonists in bal-
loon injured rat carotid arteries (49). Results from the
TREND study indicate that inhibition of Ang II formation
improves vascular function (50). However, it remains to be
determined whether this effect is primarily AT1 receptor
mediated.
Angiotensin type IV receptor and fibrinolytic system.
Plasminogen activator inhibitor C-1 (PAI-1) plays a critical
role in the balance of the fibrinolytic system. It is synthe-
sized locally in endothelium and smooth muscle cells and is
therefore important in local thrombosis. In fact, PAI-1
levels have been shown to be elevated in human atheroscle-
rotic plaques, and younger survivors of myocardial infarction
have significantly elevated PAI-1 levels (51). Angiotensin
IV stimulates endothelial release of PAI-1 through its
action on the specific AT4 receptor (52). In the HEART
study, the effect of ramipril on plasma fibrinolytic balance in
patients with acute anterior myocardial infarction demon-
strated that the ACE inhibitor treated group had a signif-
icant decrease in PAI-1 levels compared with the placebo
group (53). However, it remains to be seen whether the
increase in Ang IV formation by AT1 receptor antagonists
is of therapeutic importance.
Effects of bradykinin accumulation caused by ACE inhi-
bition. Angiotensin converting enzyme is a ubiquitous
enzyme, predominantly synthesized in endothelium, partic-
ularly in the lung. It is responsible for converting Ang I to
Ang II and for degrading bradykinin to inactive peptides
and amino acids (Fig. 1).
Hemodynamics. Angiotensin converting enzyme inhibi-
tors have significant hemodynamic effects which may be
partially mediated by bradykinin. Smooth muscle and en-
dothelial cells of muscular arteries and arterioles possess
bradykinin type 1 (B1) and bradykinin type 2 (B2) receptors
(54). There is evidence that bradykinin induced arterial
dilation is largely endothelial dependent (55). Quinaprilat
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induces arterial vasodilatation in humans, partly by increas-
ing release of nitric oxide (56), and ACE inhibition has also
been shown to enhance flow dependent endothelial dilation
in humans through a bradykinin mediated effect (57).
Additionally, bradykinin induces dilation of epicardial and
resistance coronary arteries in humans, which is NO-
dependent and enhanced by prior ACE inhibition (58).
Angiotensin converting enzyme inhibitors further promote
NO production in coronary microvessels from failing ex-
planted human hearts (59). In a study on the rat infarct
model of CHF, beneficial effects on cardiac function and
remodeling obtained by an ACE inhibitor were partially
mediated by B2 receptors (40). Dogs with CHF have high
levels of endogenous bradykinin, which has significant
positive effects on cardiac function (60). These results
together with the natriuretic effects of bradykinin (61)
suggest that the kinin system may be an important mediator
through which ACE inhibitors achieve their therapeutic
effect (62). Nevertheless, clinical studies do not support
significant hemodynamic differences between ACE inhibi-
tors and AT1 receptor antagonists (63). A possible expla-
nation may be that AT1 receptor antagonists more effec-
tively suppress AT1 receptor mediated vasoconstriction
(28), while ACE inhibitor induced hemodynamic effects are
a result of partial suppression of Ang II formation and
accumulation of bradykinin.
Ischemic cardiac events. It is believed that the pathogen-
esis of ischemic cardiac events may involve an imbalance in
the local coagulatory system. Fibrinolytic dysfunction is
thought to play a critical role in the pathogenesis of acute
ischemic events (64). Bradykinin is a potent stimulator of
tissue plasminogen activator (t-PA) release and may there-
fore have an important role in the balance of the fibrinolytic
system. Infusions of bradykinin in humans markedly ele-
vated t-PA in subjects pretreated with the ACE inhibitor
captopril or quinapril (65). However, in the HEART study,
despite a reduction of PAI-1 levels by 44%, ramipril showed
no effect on t-PA (53). Bradykinin appears to inhibit the
alpha-thrombin induced activation of platelets and therefore
may inhibit their aggregation (66). There is also suggestive
evidence that bradykinin, by acting on B1 receptors on the
surface of platelets, may influence the arachidonic acid
cascade, hence having a role in the regulation of platelet
function (67).
Angiotensin converting enzyme inhibition may augment
ischemic preconditioning, which is considered an important
cardioprotective mechanism in acute myocardial ischemia.
It has been suggested that this effect is mediated by
bradykinin, as HOE-140, a specific B2 receptor antagonist,
abolished this cardioprotective effect in human atrial trabec-
ulae (68).
Specific lipid abnormalities are established causal factors
in the pathogenesis of coronary vascular disease. Oxidized
LDL is a powerful atherogenic agent. In a study on rat aorta
incubated in human oxidized LDL, ramipril prevented the
development of endothelial dysfunction probably via a B2
receptor mediated effect, while losartan (AT1 receptor
antagonist) did not (69).
These potentially beneficial effects of bradykinin on
ischemic cardiac events might explain the decrease in
ischemic events by ACE inhibition as shown in the SAVE-
trial (11). However, the effect of bradykinin on ischemia
may be diminished in patients with endothelial dysfunction
and the effect may differ between species (62).
Adverse effects. Angiotensin converting enzyme inhibitor
induced cough may be a result of bradykinin accumulation;
inhaled bradykinin has been shown to significantly increase
airway hyperresponsiveness to allergenic stimuli in sheep
(70). In patients with ACE inhibitor induced cough, a
significant correlation between intradermal inflammatory
response to bradykinin and incidence of cough has been
shown (71). Thromboxane A2 may play an important role
in kinin-mediated cough. Angiotensin-converting enzyme
inhibitor cough has been shown to be significantly reduced
in humans by the use of thromboxane synthetase antago-
nists (72,73).
Angioedema is a potentially life-threatening complica-
tion of ACE inhibitor therapy with an incidence of 0.1% to
0.2% (74). The pathophysiology is poorly understood;
however, a recent human study showed significant eleva-
tions in plasma bradykinin during acute attacks of captopril
induced angioedema (75). There may be racial differences in
susceptibility to ACE inhibitor induced angioedema;
African-Americans have a greater sensitivity to accumula-
tion of bradykinin and an increased incidence of angio-
edema (76).
Renal dysfunction is a well-recognized complication of
ACE inhibitor therapy, particularly in cardiac failure, which
may be partially mediated by bradykinin accumulation.
Since bradykinin causes a NO-dependent renal vasodilata-
tion (77), it may lead to a drop in renal perfusion pressure in
situations where systemic and renal pressure are borderline.
Nevertheless, there was no difference in renal dysfunction in
the ELITE trial comparing captopril and losartan (78).
Angiotensin and the sympathetic nervous system. Acti-
vation of the sympathetic nervous system is believed to be of
importance in the progressive nature of cardiac failure and
the high incidence of sudden death (79,80). Chronic ACE
inhibition in CHF may reduce sympathetic activity (81,82)
and augment baroreflex control of sympathetic activity in
CHF (83). Baroreflex control of sympathetic outflow in
rabbits is also improved by losartan (84). Angiotensin II
type 1 blockade and ACE inhibition produce similar de-
creases in cardiac beta-adrenergic signal transduction in
transgenic rats with cardiac failure (85). Angiotensin-
converting enzyme inhibition enhances cardiac responsive-
ness to adrenergic stimuli which is depressed by beta-
receptor down-regulation in individuals with left ventricular
dysfunction (86). Whether these effects are due to direct
inhibition of the sympathetic nervous system or as a
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consequence of hemodynamic improvement is unknown.
However, Ang II increases noradrenaline release from atria
by acting on AT1 receptors in isolated guinea pig hearts
(87). Given the more complete blockade of AT1 receptor
mediated effects, AT1 receptor blockade may result in a
more complete suppression of the sympathetic nervous
system. In addition, bradykinin releases noradrenaline as a
reflex response (88). Angiotensin II type 1 receptor antag-
onists may also directly decrease central sympathetic tone
since there is a high concentration of AT1 receptors in the
rostral ventrolateral medulla, a region involved in modula-
tion of sympathetic vasomotor tone (89), and AT1 receptor
antagonists may pass the blood-brain barrier more easily
than ACE inhibitors (45). However, unopposed AT2 re-
ceptors in the adrenal gland may elicit the local release of
catecholamines (90).
The maintenance of sodium balance by the kidney is
regulated in part by sympathetic activity, and renal sympa-
thetic tone is high in human CHF (91). In rats with
experimental CHF, losartan improved cardiac baroreflex
regulation of renal sympathetic nerve activity. This was
associated with improved ability to excrete acute and
chronic sodium loads (92). Renal sympathetic inhibition
may underlie the ability of both AT1 antagonists and ACE
inhibitors to prevent cardiac decompensation by counteract-
ing volume overload.
The available data suggests that ACE inhibitors and AT1
antagonists may have differing effects on sympathetic activ-
ity in CHF; however, it is likely that both drug classes act
favorably in this regard.
CLINICAL COMPARISON OF ACE INHIBITION AND
AT1-RECEPTOR ANTAGONISM IN HEART FAILURE
There have recently been reported several small, short term
studies investigating the effects of AT1 receptor antagonists
as compared with those of ACE inhibitors on symptoms,
hemodynamics, neurohormones and exercise capacity in
patients with CHF. They suggest that both classes of drugs
are equally effective with respect to these endpoints. The
first reports comprised a comparison of losartan with ena-
lapril in two parallel, randomized studies including 166 and
112 patients with symptomatic CHF (93,94). Both drugs
had comparable effects on symptoms, exercise capacity and
neurohormones over a period of 8 to 12 weeks. More recent
studies investigating losartan (95), irbesartan (96) and val-
sartan (63) as compared with ACE inhibition, confirmed
these results. No study as yet has directly compared the
different AT1 receptor antagonists. It is therefore impossi-
ble to say at this stage whether there will be clinically
relevant differences between the various AT1 receptor an-
tagonists in patients with CHF.
ELITE was the first study of sufficient size (n 5 722) and
duration (follow-up, 48 weeks) to allow comment on
relative survival benefits (78). The AT1 receptor antagonist
losartan was compared with the ACE inhibitor captopril in
patients with a left ventricular ejection fraction #40%.
Perhaps surprisingly, survival was significantly better with
losartan, largely attributable to lower sudden cardiac death
rate. In addition, losartan was better tolerated, although the
primary end-point—renal dysfunction—was similar in both
groups. The authors concluded that losartan has an apparent
mortality advantage over captopril. However, the difference
in sudden cardiac death between the two groups in absolute
numbers was only nine (5 vs. 14) (78). It is also important
to note that this study was not designed to have significant
statistical power to show any difference in mortality (62).
RESOLVD, a study similar in size to ELITE, included
769 patients with symptomatic systolic left-ventricular dys-
function followed for a period of ten months. The AT1
receptor antagonist candesartan at three different doses
(4 mg, 8 mg and 16 mg daily) was compared with the ACE
inhibitor enalapril alone and the combination of both drugs
(97). Although this study was also not designed to show any
effects on mortality, it is remarkable that the trend was the
opposite of the ELITE study, showing a better outcome
with the ACE inhibitor (p 5 0.15). A direct comparison
between the RESOLVD and ELITE studies is not possi-
ble, in part because the data from the RESOLVD study has
been published only in abstract form. However, given the
similar effects of captopril and enalapril on survival in a
broad range of patients (7), the decrease in mortality of 46%
by losartan (ELITE) and the increase in mortality by
candesartan of 60% (RESOLVD), the results might trans-
late in a cross-study comparison into a mortality rate
approximately three times higher on candesartan than on
losartan. Such a huge difference is improbable and empha-
sizes the randomness of trial results which can be achieved
with statistically underpowered studies. Accordingly,
whether AT1 antagonists are beneficial in CHF remains to
be elucidated. Until larger mortality trials comparing ACE
inhibitors with AT1 receptor antagonists are available, the
use of AT1 antagonists in CHF will remain investigational
and ACE inhibitors remain first line treatment in CHF.
Combined therapy of ACE inhibition and AT1 receptor
antagonism. As discussed in detail above, it is possible that
bradykinin accumulation contributes to the beneficial effects
of ACE inhibitors. In addition, AT1 receptors mediate
most of the harmful effects of Ang II. Thus, the incomplete
suppression of AT1 receptor mediated effects and the
accumulation of bradykinin by ACE inhibitors provide
rationale for the combination of ACE inhibitors and AT1
receptor antagonists in the therapy of CHF. However, the
role and effectiveness of such a combination remains to be
better defined. In the RESOLVD study, remodeling of the
left ventricle, plasma levels of natriuretic peptides and
suppression of aldosterone production were beneficially
influenced by the combination of candesartan and enalapril,
as compared to either drug alone which led to similar
results. There was no significant difference in tolerability
between the different groups (97). In addition, hemody-
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namic benefits have been observed after administration of
valsartan in combination with an ACE inhibitor (98) and
adding losartan to conventional therapy improved left ven-
tricular ejection fraction and volumes (99). Despite the
further reduction in blood pressure observed on adding
losartan, no symptomatic hypotension or renal dysfunction
was observed (100). Whether the combination of ACE
inhibition and AT1 receptor antagonism will achieve
greater benefits on morbidity and mortality than either of
these agents alone remains to be determined in large
multicenter trials which are being conducted.
UNDERUTILIZATION AND SUBOPTIMAL DOSAGE
OF ACE INHIBITORS IN CLINICAL PRACTICE:
ARE AT1-RECEPTOR ANTAGONISTS THE SOLUTION?
Despite the clear evidence that ACE inhibitors improve
survival, only about 30 to 50% of CHF patients actually
receive ACE inhibitors (101,102). Some are not on ACE
inhibitors secondary to tolerability problems, but the pro-
portion that falls into this category is largely unknown.
However, even in the setting of tertiary medical care with a
much higher use of ACE inhibition (103,104) than in
general patient populations (101), many of those not taking
ACE inhibitors could probably tolerate them (104). Ac-
cordingly, the underuse of this evidence-based therapy in
the general population seems to be only infrequently caused
by intolerability.
Additionally, the majority of patients on ACE inhibitors
receive doses lower than the dosages used in the large
clinical trials (105). However, high doses of ACE inhibition
are superior to low doses with respect to symptoms (106),
exercise performance (107,108) and suppression of neuro-
humoral stimulation (12,33,108). The recently completed
ATLAS study (109) reported at the 1998 meeting of the
American College of Cardiology included 3,164 CHF
patients (follow-up, 46 months). It demonstrated a trend
towards an eight percent lower mortality (p 5 0.13) and a
significant decrease in the combined endpoint of death and
hospitalization of 12 percent (p 5 0.002) in the high dose as
compared with the low dose group (mean difference 19 mg
lisinopril). Although the NETWORK study, which was
probably statistically underpowered, showed no significant
difference in the combined endpoint of death and hospital-
ization in 1,500 patients on 10, 20 and 40 mg enalapril for
six months (110), it is likely that high doses of ACE
inhibitors are also beneficial with respect to prognosis.
Based on the results of several studies (101,102,104,111),
a recent editorial has concluded that the most important
reasons for nonprescription of ACE inhibitors appears to be
lack of familiarity with the drug and concerns about safety
and adverse reactions, especially hypotension, renal failure
and cough (112). This may also account for widespread use
of low dose ACE inhibition. Even though there appears to
be a relationship between ACE inhibitor dosage and sever-
ity of adverse effects (113), tolerability of high doses is not
a major problem in most patients (110). It might be argued
that the introduction of AT1 receptor antagonists, better
tolerated than ACE inhibitors, will considerably increase
the appropriate prescription of drugs influencing the RAS
in CHF patients (62).
Tolerability of ACE inhibitors and AT1 receptor antag-
onists. Hypotension is probably the most important reason
for concern regarding the use of ACE inhibitors in CHF.
Early reports of severe hypotensive reactions using high
initial doses (114–116) may still support these concerns.
However, hypotensive response is dependent on initial dose
and concomitant therapy, particularly diuretics (10,117–
119). Accordingly, patients often tolerate even maximal
doses of ACE inhibitors (110) if the initial dose is kept low,
uptitration is slow and diuretic dosage is stable (120).
Available reports in CHF patients do not support the
premise that hypotensive responses occur less often with
AT1 receptor antagonists than with ACE inhibitors
(78,93,94), even if the hypotensive effect of ACE inhibitors
is partly mediated by bradykinin accumulation (121,122).
Renal dysfunction, principally due to diminished renal
perfusion, is common in CHF patients and signals caution
when utilizing ACE inhibitors. However, despite a signif-
icant worsening of renal function in up to one-third of these
patients after initiation of ACE inhibition, most patients
show only a mild increase in serum creatinine, and ACE
inhibitor therapy does not have to be discontinued (123). In
fact, a recent, randomized, placebo-controlled study showed
that over the course of three years renal function was
significantly improved by ACE inhibition in patients with
renal dysfunction, despite an initial rise in serum creatinine
of 10% to 15% (124). Again, AT1 receptor antagonists do
not seem to be substantially superior to ACE inhibitors with
respect to renal function despite experimental evidence for
better renal tolerability of AT1 receptor antagonists (125).
The incidence of persistent renal dysfunction was not
different between losartan and captopril in the ELITE study
(78).
It is well-documented that up to one-third of patients
develop dry cough during therapy with ACE inhibitors
(126,127). Although differences between individual ACE
inhibitors have not been fully excluded (128), cough sec-
ondary to ACE inhibition is probably related to accumula-
tion of kinins and therefore a class effect (129,130). How-
ever, cough may be aggravated by pulmonary congestion.
Indeed, in a recent trial, a decrease in dry cough was found
in some patients when increasing enalapril dosage was
accompanied by an improvement in clinical symptoms and
neurohumoral stimulation (113).
In patients not able to tolerate cough, AT1 receptor
antagonism is a good alternative (131,132). However, only
3.8% of the patients enrolled in ELITE discontinued
captopril because of cough (78). Furthermore, discontinua-
tion rate was not different in the various groups in the
RESOLVD study (97).
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Finally, underutilization of evidence-based medicine is a
general problem not limited to the use of ACE inhibitors
(133–135). Even the good tolerability accorded to AT1
antagonists may not be enough to “avoid” underutilization.
Conclusions. The discussion of whether ACE inhibitors,
AT1 receptor antagonists or the combination of both are
superior in the pharmacotherapy of CHF is largely theoret-
ical. Accordingly, AT1 receptor antagonists remain inves-
tigational at present and are reserved for patients with
intolerance to ACE inhibition. Angiotensin-converting en-
zyme inhibitors remain first line therapy in patients with
CHF due to systolic dysfunction unless contraindicated. An
emphasis should be placed on increasing the utilization of
ACE inhibitors, as more than 50 percent of patients with
CHF do not receive ACE inhibitors. In addition, the
majority of those on ACE inhibitors receive doses lower
than the dosage used in the large clinical trials. Although
not yet completely proved, it is likely that high doses of
ACE inhibition are superior to low doses with respect to
prognosis and symptoms.
Apart from establishing the place, if any, of AT1 receptor
antagonists in the primary therapy of CHF, it remains to be
seen whether all AT1 receptor antagonists will confer
similar benefits. In addition, the value of combined therapy
with ACE inhibitors and AT1 receptor antagonists needs to
be determined. Finally, equivalent doses of ACE inhibitors
and AT1 receptor antagonists remain to be defined.
An increasingly important consideration will be the value
of RAS antagonism in combination with a variety of other
medication such as beta-adrenergic blocking agents, central
inhibitors of the sympathetic nervous system (e.g., imida-
zoline type 1 receptor agonists), endothelin antagonists,
endopeptidase inhibitors and new generation calcium chan-
nel blockers. The predominant challenge in the future
management of CHF will be to tailor medical therapy
individually by selecting from a range of drugs proven
beneficial for each patient. Hypotension is likely to be a key
limiting factor with multiple drug use. Therefore, a more
individualized therapeutic approach will likely be necessary,
as opposed to a standardized therapeutic regime for all
patients with CHF. Criteria for such an individualized
approach, however, are largely unknown and remain to be
defined.
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